Who is affected by this change?

This affects Independence Blue Cross Oncology, Endocrinology, Urology, OB-GYN providers on Commercial plans.

When does this change take effect?

This change is effective Oct 1, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.01.33k, Leuprolide Acetate (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)

Independence Blue Cross·Oncology, Endocrinology, Urology +1 more·Pharmacy

Effective date

Oct 1, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is an updated pharmacy policy for Leuprolide Acetate medications including Camcevi™, Eligard®, Fensolvi®, and Lupron Depot®. The policy affects commercial insurance plans and becomes effective October 1, 2025.

Action Required

Action needed

By October 1, 2025: Review the complete policy details at the provided URL to understand specific coverage changes for Leuprolide Acetate medications (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®). Update billing procedures and prior authorization requirements as specified in the full policy. Ensure staff are aware of any new coverage criteria or documentation requirements for these hormone therapy medications.

Related policy hubs

Independence Blue Cross policies Oncology Endocrinology Urology OB-GYN